Clinical Trials


A Study of Capravirine Plus VIRACEPT Plus Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients Who Failed Previous Anti-HIV Treatments

This study has been completed
Agouron Pharmaceuticals

Information provided by (Responsible Party)
NIH AIDS Clinical Trials Information Service Identifier

First received: September 11, 2000
Last updated: June 23, 2005
Last Verified: March 2001
History of Changes


The purpose of this study is to see if the addition of capravirine to VIRACEPT (nelfinavir mesylate) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) is an effective combination drug therapy for HIV patients who have failed a nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy.

Condition Intervention Phase
HIV Infections

Drug : Capravirine
Drug : Nelfinavir mesylate
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: A Double-Blind, Randomized, Placebo-Controlled Study of Capravirine (AG1549) in Combination With VIRACEPT and Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Subjects Who Failed an Initial Nonnucleoside Reverse Transcriptase Inhibitor Containing Regimen

Further study details as provided by NIH AIDS Clinical Trials Information Service:

Enrollment: 350
Study Start Date: February 2000
Study Completion Date: April 2001

Detailed Description:

[Note: As of 2/28/2001, due to toxicity studies and concern for safety, patients need to sign new informed consents. Patients who are taking capravirine and who currently have viral loads below 400 copies/ml may continue to take capravirine at 1400 mg twice daily. Capravirine will be discontinued in patients with viral loads greater than 400 copies/ml at their last visit and they will be switched to new therapies or continue with their background therapies as deemed appropriate by the investigators.] This study will take place in approximately 150 centers in the US, Canada, Europe, Australia, Argentina, and South Africa. Patients are randomized to 1 of 2 treatment groups and stratified by geographic sites (North American and non-North American), plasma HIV-1 RNA levels, and prior NNRTI use. Group 1 patients receive capravirine plus VIRACEPT plus 2 new NRTIs and Group 2 patients receive capravirine placebo plus VIRACEPT plus 2 new NRTIs. NRTIs will not be provided by the sponsor. Patients may remain on their assigned treatment for 48 weeks, with posttherapy follow-up occurring at 1 and 3 months. Assessments, done at various times throughout the study, include medical history, HIV antibody test, complete or symptom-directed physical examination, vital signs, height, weight, serum pregnancy test, hematology, chemistry, and recording of concomitant medications and adverse events. Other select assessments are performed at specified visits. Plasma samples for resistance testing and blood specimens for peripheral blood mononuclear cells (PBMC) are obtained at several times. The plasma samples and PBMCs may be used for viral drug resistance testing. Blood samples for quantitation of capravirine, VIRACEPT, and M8 (a metabolite of VIRACEPT) plasma concentrations are collected several times. Additional blood samples for analysis of drug concentrations may be requested depending on concomitant NRTIs or other medications. A Data Safety Monitoring Board monitors patient safety at prescribed intervals during the study.



Ages Eligible for Study: 18 Years and older  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  


Inclusion Criteria
Patients may be eligible for this study if they:

  • Are HIV positive.
  • Are at least 18 years old.
  • Are currently taking an NNRTI and at least 1 NRTI for at least 28 days and failing that therapy. (Patients who began an NRTI therapy without an NNRTI and then added an NNRTI may also enroll.)
  • Are on the current NNRTI plus NRTI therapy at the time of the screening visit.
  • Have a CD4 count greater than 50/mm3 and viral load greater than 2,000 copies/ml at the screening visit.
  • Have adequate blood, kidney, and liver functions.
  • Agree to use a barrier method of birth control while on the study.
  • Agree to use additional methods of birth control if less than 2 years postmenopausal.

  • Exclusion Criteria
    Patients will not be eligible for this study if they:
  • Are using or have received other investigative drugs within 28 days of receiving the first dose of study drug.
  • Are using or have received any medications or radiation treatments that interfere with the study drug within 28 days of receiving the first dose of study drug.
  • Have had prior treatment with capravirine or any protease inhibitors.
  • Are pregnant or breast-feeding.
  • Have an active infection or serious medical condition.
  • Have a mental, social, or addictive disorder that may interfere with study treatment.

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00006211


United States, California
Lisa Bauman
San Diego, California, United States, 92121

Sponsors and Collaborators

Agouron Pharmaceuticals
More Information

More Information

Responsible Party: Agouron Pharmaceuticals Identifier: NCT00006211   History of Changes  
Other Study ID Numbers: 286E  
Study First Received: September 11, 2000  
Last Updated: June 23, 2005  

Keywords provided by NIH AIDS Clinical Trials Information Service:

Drug Therapy, Combination
HIV Protease Inhibitors
Reverse Transcriptase Inhibitors
Anti-HIV Agents
Viral Load

Additional relevant MeSH terms:
HIV Infections
Reverse Transcriptase Inhibitors
Nelfinavir processed this data on January 28, 2020
This information is provided by